Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W. Roloff, George Yaghmour, Ibrahim Aldoss et al.|Journal of Clinical Oncology|2024Cited by 36
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical TrialsChenyu Lin, Mitchell E. Horwitz, Guillermo Sanz et al.|Transplantation and Cellular Therapy|2023Cited by 16
Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord BloodChenyu Lin, Anthony D. Sung, Gautam Sajeev et al.|Transplantation and Cellular Therapy|2022Cited by 12
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Betsy Blunk, Gregory W. Roloff et al.|Blood Advances|2024Cited by 12
Spectrum, prevalence, and clinical correlates of <i>PPM1D</i> mutations in patients with clonal hematopoiesis and clonal cytopeniasTalha Badar, Mrinal M. Patnaik, Ludovica Marando et al.|Blood Advances|2026Cited by 4